Physician profile

Robert Dale

Podiatrist · Buckhannon, WV

NPI 1679666911

$1,242.17

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$901.55
Food and Beverage$53.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Treace Medical Concepts, INC. $901.55 2023
Organogenesis INC. $133.77 2021-2022
Paratek Pharmaceuticals, INC. $82.31 2021
Horizon Therapeutics Plc $27.93 2022
Abbvie INC. $20.77 2024
Bioventus LLC $17.00 2024 Exogen Ultrasound Bone Healing System
Convatec INC. $15.48 2024
Paragon 28, INC. $14.74 2019
Alfasigma USA, INC. $14.54 2022
Medline Industries LP $14.08 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Dale

$1,242.17

in general payments reported 2019-2025

Years
2019-2024
Top company
Treace Medical Concepts, INC.

https://glasscript.com/doctor/257606/robert-dale

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.